Drug treatment of Type 2 diabetes: its cost is significantly associated with HbA1c levels

Aims: to examine the relationship between costs of hyperglycemia drug treatment and glycemic control among people with type 2 diabetes (T2D). Methods: This observational study utilized data from the QUALIDIAB database on 3,452 T2D patients seen in Diabetes Centers in Argentina. Patients were classif...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Elgart, Jorge Federico, Silvestrini Viola, Constanza, Prestes, Mariana, González, Lorena, Rucci, Enzo, Gagliardino, Juan José
Formato: Articulo
Lenguaje:Inglés
Publicado: 2019
Materias:
Ciencias Médicas
Ciencias Económicas
tratamiento de drogas
control de glucemia
diabetes mellitus
País en desarrollo
Acceso en línea:http://sedici.unlp.edu.ar/handle/10915/142726
Aporte de:
SEDICI (UNLP) de Universidad Nacional de La Plata
id I19-R120-10915-142726
record_format dspace
institution Universidad Nacional de La Plata
institution_str I-19
repository_str R-120
collection SEDICI (UNLP)
language Inglés
topic Ciencias Médicas
Ciencias Económicas
tratamiento de drogas
control de glucemia
diabetes mellitus
País en desarrollo
spellingShingle Ciencias Médicas
Ciencias Económicas
tratamiento de drogas
control de glucemia
diabetes mellitus
País en desarrollo
Elgart, Jorge Federico
Silvestrini Viola, Constanza
Prestes, Mariana
González, Lorena
Rucci, Enzo
Gagliardino, Juan José
Drug treatment of Type 2 diabetes: its cost is significantly associated with HbA1c levels
topic_facet Ciencias Médicas
Ciencias Económicas
tratamiento de drogas
control de glucemia
diabetes mellitus
País en desarrollo
description Aims: to examine the relationship between costs of hyperglycemia drug treatment and glycemic control among people with type 2 diabetes (T2D). Methods: This observational study utilized data from the QUALIDIAB database on 3,452 T2D patients seen in Diabetes Centers in Argentina. Patients were classified according to their HbA1c value into two groups: On Target (OT; HbA1c≤7%), and Not on Target (NOT; HbA1c>7%); within each category we considered clinical and metabolic indicators, as well as type of hyperglycemia treatment. Monthly expenditure on drugs was estimated by micro‐costing. Multivariable regression analysis was used to evaluate the association between cost of hyperglycemia treatment and HbA1c values. Results: 48.9% of the participants have HbA1c on target values. Overall monthly per capita costs of this treatment increased significantly (134%) in the NOT group. Multivariable regression analysis showed that expenditure for hyperglycemia drugs treatment was significant associated with glycemic control (OR:0.705), diabetes duration (OR:1.017), systolic blood pressure (OR:1.006), and treatment of T2D (OR:2.622). Conclusions: HbA1c not on target significantly increases drugs monthly cost of hyperglycemia treatment in people with T2D in a country with an emerging market economy. This article is protected by copyright. All rights reserved.
format Articulo
Articulo
author Elgart, Jorge Federico
Silvestrini Viola, Constanza
Prestes, Mariana
González, Lorena
Rucci, Enzo
Gagliardino, Juan José
author_facet Elgart, Jorge Federico
Silvestrini Viola, Constanza
Prestes, Mariana
González, Lorena
Rucci, Enzo
Gagliardino, Juan José
author_sort Elgart, Jorge Federico
title Drug treatment of Type 2 diabetes: its cost is significantly associated with HbA1c levels
title_short Drug treatment of Type 2 diabetes: its cost is significantly associated with HbA1c levels
title_full Drug treatment of Type 2 diabetes: its cost is significantly associated with HbA1c levels
title_fullStr Drug treatment of Type 2 diabetes: its cost is significantly associated with HbA1c levels
title_full_unstemmed Drug treatment of Type 2 diabetes: its cost is significantly associated with HbA1c levels
title_sort drug treatment of type 2 diabetes: its cost is significantly associated with hba1c levels
publishDate 2019
url http://sedici.unlp.edu.ar/handle/10915/142726
work_keys_str_mv AT elgartjorgefederico drugtreatmentoftype2diabetesitscostissignificantlyassociatedwithhba1clevels
AT silvestriniviolaconstanza drugtreatmentoftype2diabetesitscostissignificantlyassociatedwithhba1clevels
AT prestesmariana drugtreatmentoftype2diabetesitscostissignificantlyassociatedwithhba1clevels
AT gonzalezlorena drugtreatmentoftype2diabetesitscostissignificantlyassociatedwithhba1clevels
AT ruccienzo drugtreatmentoftype2diabetesitscostissignificantlyassociatedwithhba1clevels
AT gagliardinojuanjose drugtreatmentoftype2diabetesitscostissignificantlyassociatedwithhba1clevels
bdutipo_str Repositorios
_version_ 1764820460030132224

Ejemplares similares